دورية أكاديمية
Enzalutamide Prior to Radium-223 Is Associated with Better Overall Survival in Metastatic Castration-Resistant Prostate Cancer Patients Compared to Abiraterone—A Retrospective Study
| العنوان: | Enzalutamide Prior to Radium-223 Is Associated with Better Overall Survival in Metastatic Castration-Resistant Prostate Cancer Patients Compared to Abiraterone—A Retrospective Study |
|---|---|
| المؤلفون: | Hao Xiang Chen, Li-Hsien Tsai, Chao-Hsiang Chang, Hsi-Chin Wu, Ching-Chan Lin, Che-Hung Lin, Chin-Chung Yeh, Chi-Rei Yang, Chi-Shun Lien, Yi-Huei Chang, Ji-An Liang, Guan-Heng Chen, Po-Jen Hsiao, Po-Fan Hsieh, Chi-Ping Huang |
| المصدر: | Cancers, Vol 15, Iss 13, p 3516 (2023) |
| بيانات النشر: | MDPI AG, 2023. |
| سنة النشر: | 2023 |
| المجموعة: | LCC:Neoplasms. Tumors. Oncology. Including cancer and carcinogens |
| مصطلحات موضوعية: | metastatic castration resistant prostate cancer, abiraterone, enzalutamide, radium-223, sequence, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282 |
| الوصف: | Metastatic castration-resistant prostate cancer (mCRPC) is a progressive stage of prostate cancer that often spreads to the bone. Radium-223, a bone-targeting radiopharmaceutical, has been shown to improve the overall survival in mCRPC in patients without visceral metastasis. However, the impact of prior systemic therapy on the treatment outcome of mCRPC patients receiving radium-223 remains unclear. This study aimed to investigate the optimal choice of systemic therapy before radium-223 in mCRPC patients. The study included 41 mCRPC patients who received radium-223 therapy, with 22 receiving prior enzalutamide and 19 receiving prior abiraterone. The results showed that the median overall survival was significantly longer in the enzalutamide group than in the abiraterone group (25.1 months vs. 14.8 months, p = 0.049). Moreover, the number of patients requiring blood transfusion was higher in the abiraterone group than in the enzalutamide group (9.1% vs. 26.3%, p = 0.16). The study also found that the number of doses of Radium-223 received was significantly associated with overall survival (≥5 vs. p = 0.001). Our study provides insights into the optimal treatment choice for mCRPC prior to radium-223, indicating that enzalutamide prior to radium-223 administration may have better outcomes compared to abiraterone in mCRPC patients without visceral metastasis. |
| نوع الوثيقة: | article |
| وصف الملف: | electronic resource |
| اللغة: | English |
| تدمد: | 15133516 2072-6694 |
| Relation: | https://www.mdpi.com/2072-6694/15/13/3516; https://doaj.org/toc/2072-6694 |
| DOI: | 10.3390/cancers15133516 |
| URL الوصول: | https://doaj.org/article/e5afeb033cc14f2caa3eec04eaacec0b |
| رقم الأكسشن: | edsdoj.5afeb033cc14f2caa3eec04eaacec0b |
| قاعدة البيانات: | Directory of Open Access Journals |
Full Text Finder | تدمد: | 15133516 20726694 |
|---|---|
| DOI: | 10.3390/cancers15133516 |